Spero Therapeutics (NASDAQ:SPRO) Stock Passes Above 200 Day Moving Average – Here’s What Happened

Spero Therapeutics, Inc. (NASDAQ:SPRO) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.25 and traded as high as $2.26. Spero Therapeutics shares last traded at $2.23, with a volume of 682,738 shares.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Spero Therapeutics in a report on Thursday, January 22nd. Wall Street Zen raised Spero Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, January 11th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce”.

Spero Therapeutics Price Performance

The firm’s 50 day moving average price is $2.36 and its 200-day moving average price is $2.25. The stock has a market cap of $125.64 million, a P/E ratio of -2.82 and a beta of 1.45.

Insider Transactions at Spero Therapeutics

In other Spero Therapeutics news, insider Esther Rajavelu sold 87,917 shares of the stock in a transaction on Friday, February 6th. The stock was sold at an average price of $2.36, for a total transaction of $207,484.12. Following the sale, the insider directly owned 1,012,091 shares in the company, valued at approximately $2,388,534.76. This trade represents a 7.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Quadrature Capital Ltd purchased a new stake in shares of Spero Therapeutics during the fourth quarter valued at $88,000. Millennium Management LLC purchased a new position in Spero Therapeutics in the 4th quarter worth about $56,000. Intrepid Family Office LLC lifted its stake in Spero Therapeutics by 50.0% during the 4th quarter. Intrepid Family Office LLC now owns 165,000 shares of the company’s stock valued at $384,000 after acquiring an additional 55,000 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of Spero Therapeutics during the 4th quarter valued at about $278,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Spero Therapeutics in the fourth quarter worth approximately $306,000. 25.60% of the stock is owned by institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.